Study Highlights**WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?**☑ The pharmacokinetics of dapsone have not been characterized in overweight or obese people, a problem since the world population has become increasingly obese.**WHAT QUESTION DOES THIS STUDY ADDRESS?**☑ This study characterizes the population pharmacokinetics, including covariate effects, of dapsone in overweight and obese adults from the United States.**WHAT THIS STUDY ADDS TO OUR KNOWLEDGE**☑ Weight and age were identified as having an impact on dapsone pharmacokinetics, based on the use of Multivariate adaptive regression splines (MARS), an artificial intelligence algorithm that enables delineation of nonlinear relationships and high‐order interactions. The effect was nonlinear and discontinuous at some values.**HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?**☑ MARS allows a simpler approach to identify pharmacokinetic covariates and their nonlinear interactions using smaller sample sizes, compared to standard approaches. The complex relationships identified for dapsone suggest the need to redefine doses in obese and older patients.

 {#psp412208-sec-0001}

Dapsone \[4--4′‐diaminodiphenyl sulphone\] was first synthesized by Fromm and Wittman in 1908.[1](#psp412208-bib-0001){ref-type="ref"} It is one of the most commonly used pharmacological compounds on the globe, given its mode of activity as a competitive inhibitor of para‐amino benzoic acid in the evolutionarily conserved folate synthesis pathway.[1](#psp412208-bib-0001){ref-type="ref"} This mechanism gives it a broad spectrum of activity against *Mycobacterium leprae*, fungi, and parasites of global health significance such as *Plasmodium falciparum* and *Toxoplasma gondii*. In addition, dapsone inhibits neutrophil activity, and is prescribed for this immunomodulatory role in several dermatological disorders, as well as brown recluse spider bite wounds.[1](#psp412208-bib-0001){ref-type="ref"} Given the important role of the relationship between drug concentrations achieved in patients and therapy failure as well as acquired drug resistance and other pharmacodynamics outcomes, it is imperative to identify the factors responsible for dapsone pharmacokinetic variability.[2](#psp412208-bib-0002){ref-type="ref"}, [3](#psp412208-bib-0003){ref-type="ref"}, [4](#psp412208-bib-0004){ref-type="ref"}, [5](#psp412208-bib-0005){ref-type="ref"}, [6](#psp412208-bib-0006){ref-type="ref"} One factor that has emerged as an important pharmacokinetic covariate for many antiinfective agents is patient weight; specifically, weight increases beyond 66.3 kg.[7](#psp412208-bib-0007){ref-type="ref"}, [8](#psp412208-bib-0008){ref-type="ref"}, [9](#psp412208-bib-0009){ref-type="ref"}, [10](#psp412208-bib-0010){ref-type="ref"} This pharmacokinetic covariate is a concern since the human species is becoming obese, and most adults have weight above 66.3 kg. High‐level obesity is now encountered across the globe, with an estimated 2 billion people now considered obese, who also live in the very countries where dapsone is used extensively.[11](#psp412208-bib-0011){ref-type="ref"}, [12](#psp412208-bib-0012){ref-type="ref"}, [13](#psp412208-bib-0013){ref-type="ref"}, [14](#psp412208-bib-0014){ref-type="ref"}

Obesity is defined using the interaction parameter, body mass index (BMI), with weight (kg) and height in meters (m) interacting. Overweight is a BMI ≥25 kg/m^2^ and obesity a BMI ≥30 kg/m^2^. In the case of dapsone, the impact of weight on drug concentrations has been assumed to be linear through all ranges, such that both systemic clearance and volume of distribution have been considered to increase linearly for each 1 kg increase above body mass (colloquial term "weight"), not BMI.[15](#psp412208-bib-0015){ref-type="ref"}, [16](#psp412208-bib-0016){ref-type="ref"} However, based on some of our prior studies, such linear relationships in biologic systems over a wide range of values should be suspect.[8](#psp412208-bib-0008){ref-type="ref"}, [9](#psp412208-bib-0009){ref-type="ref"}, [17](#psp412208-bib-0017){ref-type="ref"}, [18](#psp412208-bib-0018){ref-type="ref"}, [19](#psp412208-bib-0019){ref-type="ref"}, [20](#psp412208-bib-0020){ref-type="ref"} Moreover, the effect of weight on pharmacokinetics in the ranges of up to 150 kg, now increasingly encountered in patients, has hitherto not been investigated for dapsone. Prior studies have been of relatively underweight patients and mixtures of babies and adults.[15](#psp412208-bib-0015){ref-type="ref"}, [16](#psp412208-bib-0016){ref-type="ref"}, [21](#psp412208-bib-0021){ref-type="ref"} Here, we optimized a clinical experimental study design to more precisely identify the effects of obesity on dapsone pharmacokinetic parameters.

Using the example of trimethoprim‐sulfamethoxazole, we found that if experimental design is optimized and sampling times are optimized, machine‐learning algorithms such as multivariate adaptive regression splines (MARS) can robustly identify covariates of pharmacokinetic parameters with as few as 36 patients.[22](#psp412208-bib-0022){ref-type="ref"} Here we utilized the same strategy, design, and sample size for dapsone. We recruited subjects of different weights by stratifying by BMI groups and gender in the study design, so that enough subjects of different weight ranges of up to 150 kg could be studied. Second, we performed intensive pharmacokinetic sampling at eight timepoints in each patient over 72 h, to allow greater precision and minimum bias in identifying pharmacokinetic parameter estimates. Third, we utilized MARS to simultaneously identify linear and nonlinear interactions between potential covariates and pharmacokinetic parameters. All potential covariates were included *in toto* for a single implementation of the model, without presupposing the nature of any interactions. MARS, introduced by Jerome Freidman in 1991, is a machine‐learning method that does not have linearity assumptions and does not need the data to follow a specific distribution.[23](#psp412208-bib-0023){ref-type="ref"}, [24](#psp412208-bib-0024){ref-type="ref"}, [25](#psp412208-bib-0025){ref-type="ref"}

METHODS {#psp412208-sec-0002}
=======

Regulatory approval and ethics {#psp412208-sec-0003}
------------------------------

The study was submitted and approved by Institutional Review Boards (IRBs) of the University of Texas Southwestern Medical Center (\#032011‐121) and the Texas Tech University Health Sciences Center (\#A10‐3591). The study was also registered on [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT01165840). All participants provided informed written consent prior to voluntary participation.

Recruitment {#psp412208-sec-0004}
-----------

We recruited three groups of 12 people (six men, six women) based on BMI (normal weight, \<25 kg/m^2^; overweight and class I/II obesity, 25--40 kg/m^2^; class III obesity, \>40 kg/m^2^) who were ≥18 years old. Participants were recruited from July 20^th^ 2010 to May 2^nd^, 2012. Participants were ineligible if they 1) were pregnant or nursing, 2) had a medical contraindication or history of allergy to dapsone, sulfones, or sulfonamides, 3) had abnormal liver function tests (transaminases \>10 times upper limit of normal, alkaline phosphatase \>5 times upper limit of normal, or a total bilirubin \>5 times upper limit of normal), or had glucose‐6‐phosphate dehydrogenase deficiency. With the same design, a sample size of 36 has been shown to be adequate in identifying the role of weight as pharmacokinetic covariate in the past.[8](#psp412208-bib-0008){ref-type="ref"}, [9](#psp412208-bib-0009){ref-type="ref"}, [10](#psp412208-bib-0010){ref-type="ref"}, [17](#psp412208-bib-0017){ref-type="ref"}, [22](#psp412208-bib-0022){ref-type="ref"}

Study procedures {#psp412208-sec-0005}
----------------

Participants were first screened in an outpatient clinic, where they had a medical history obtained and a physical examination performed. An informed consent was then obtained from participants who fulfilled the study criteria, and blood drawn for comprehensive metabolic profile, complete blood count, and glucose‐6‐phosphate dehydrogenase deficiency. The participants were then admitted to the University of Texas Southwestern Clinical Trials and Research Center (CTRC). Participants received a single oral dapsone dose of 100 mg under directly observed therapy. Vitals signs were examined and recorded 0.5, 1, 2, and 24 h after the dapsone administration. Blood draws (10 mL each) to determine dapsone concentrations were obtained at the following times: 0 h (predose), 1, 2, 4, 8, 16, and 24 h following dapsone administration, timepoints and number of samples identified in D‐optimality in ADAPT (see below). Patients were discharged from the CTRC after 24 h. Two additional blood draws were performed 48 and 72 h postdose in the CTRC outpatient clinic, for measurement of dapsone concentration as well as for complete blood count and comprehensive metabolic profile. At each timepoint, blood samples were centrifuged for plasma separation with plasma stored at −80°C for transport to the Center for Pharmacology and Experimental Therapeutics to measure dapsone concentrations.

Adverse events were ascertained through patient interview and review of laboratory data. The IRB was notified of serious adverse events within 24 h. Data safety monitoring meetings included study coordinators and investigators (R.G.H., M.A.S., T.G.). These meetings occurred after the enrollment of 12 participants (September 2010), at the time of continuing review (April 2011, April 2012) and study enrollment closure (May 2012).

Drug concentration assay {#psp412208-sec-0006}
------------------------

Plasma samples were quantified for dapsone content using a validated, liquid chromatography/tandem mass spectrometry (LC‐MS/MS) analytical method that included a Shimadzu (Columbia, MD) liquid chromatograph and AB Sciex (Foster City, CA) 5500 QTRAP tandem mass spectrometer. Unknown plasma samples (100 μL) were transferred into a 96‐well plate with glass inserts to which 100 μL sulfamethizole (internal standard, IS) was added. The plate was removed and vortex mixed for 5 min. Then 500 μL of 80:20 ACN:MeOH was transferred to each insert, after which the samples were vortex mixed for 10 min then centrifuged for 10 min, 4°C at 3,300*g*. Next, 500 μL of the supernatant was transferred to a well plate with clean inserts and evaporated to dryness using a Labconco Centrivap. The dried samples were reconstituted with 100 μL of 50:50 MeOH:DIW and analyzed by reverse phase LC‐MS/MS. Dapsone and IS were quantitated using positive electrospray ionization (+ESI) combined with multiple reaction monitoring (MRM) for the respective precursor→product ion combinations of 249.0→155.9 m/z for dapsone and 271.0→155.9 m/z for IS. The standard curve was linear (r^2^ = 0.9942) and ranged from 5 ng/mL to 1,800 ng/mL.

Pharmacokinetic modeling {#psp412208-sec-0007}
------------------------

In all, 280 dapsone concentrations were comodeled using the ADAPT 5 program of D\'Argenio et al.[26](#psp412208-bib-0026){ref-type="ref"} Steps utilized have been detailed in the past.[3](#psp412208-bib-0003){ref-type="ref"}, [8](#psp412208-bib-0008){ref-type="ref"}, [9](#psp412208-bib-0009){ref-type="ref"}, [10](#psp412208-bib-0010){ref-type="ref"}, [17](#psp412208-bib-0017){ref-type="ref"}, [22](#psp412208-bib-0022){ref-type="ref"} Briefly, initial pharmacokinetic parameters were estimated using the standard two‐stage approach, for one‐, two‐, and three‐compartment models, with and without lag, and with first‐order input and elimination. Estimates were then used for further analysis of the same compartment models using the maximum‐likelihood solution via the expectation‐maximization (MLEM) algorithm. The best compartment model was chosen based on Akaike information criteria, Bayesian information criteria (which penalizes for complexity), negative log‐likelihoods, and parsimony, as described in our prior studies.[2](#psp412208-bib-0002){ref-type="ref"}, [3](#psp412208-bib-0003){ref-type="ref"}, [4](#psp412208-bib-0004){ref-type="ref"}, [7](#psp412208-bib-0007){ref-type="ref"}, [8](#psp412208-bib-0008){ref-type="ref"}, [9](#psp412208-bib-0009){ref-type="ref"}, [10](#psp412208-bib-0010){ref-type="ref"}, [17](#psp412208-bib-0017){ref-type="ref"}, [22](#psp412208-bib-0022){ref-type="ref"}

Nonlinear system analyses to identify covariates {#psp412208-sec-0008}
------------------------------------------------

MARS was used to examine the nonlinear behavior of pharmacokinetic factors and their interactions with potential covariates. Potential covariates examined included anthropometric measures such as weight and height, demographic factors such as age and self‐identified "racial" grouping, clinical factors, and laboratory test values for comprehensive metabolic profile and complete blood count. The potential covariates were also examined for linear and nonlinear interactions between themselves. All these variables were used to independently predict systemic clearance, apparent volume of distribution, and absorption constant for each participant who had been identified using MLEM. MARS uses basis functions (BFs) to examine candidates for both main and interaction effects, which gives MARS flexible and adaptive capabilities to fit nonlinear and linear relationships and interaction components simultaneously. Individual estimates for the pharmacokinetic parameters were incorporated in the MARS algorithm. Overfitting procedures were used to grow large models with up to 15 BFs and up to two‐way interactions between them, which were then pruned back using generalized cross‐validation (GCV) function during the backward pass. Each variable was assigned a measure of predictive importance by MARS, entailing both marginal and interaction effects involving this variable. Briefly, in view of our small sample size (35 patients), MARS built a sequence of models using all available data for learning purposes, after which the optimal model was determined based on GCV, which penalized model size and degrees of freedom parameter. We set the degree of freedom at 3 and also used naïve R‐squared values to assess goodness and compare models. Change in both R^2^ and mean squared error (MSE) values were used to examine for overfit in training and test samples. Overfit thresholds were identified by large difference between training MSE and test MSE, as well as flattening or U‐curvature in test MSE with increase in model complexity. SALFORD predictive modeling software (v. 7, San Diego, CA) was used to run MARS models.

MARS is designed for situations in which the number of variables of interest (p) is relatively large when compared to the number of observations (n): colloquially defined as *p≫n*.[25](#psp412208-bib-0025){ref-type="ref"}, [27](#psp412208-bib-0027){ref-type="ref"}, [28](#psp412208-bib-0028){ref-type="ref"} MARS is a nonparametric modeling technique that builds piecewise regression models using BFs and then ranks the most influential predictors in each model using variance‐bias tradeoffs. BF are data‐driven and locally defined (not on the global data), such that the relationships between the dependent variable and the independent variables, i.e., predictors, is a set of discontinuous regression lines, each with its own slope, but joint end‐to‐end via knots or hinges. These knots represent local points in the data where the relationships or slope changes, thereby reflecting nonlinear patterns within the data. The output for MARS are given as BF to account for their nonlinear behavior of potential predictors (i.e., covariates) with the dependent variable, as well as the tendency to interact among themselves. The BFs take on several forms, which help explain what they mean. First, a BF can be a simple hinge function that takes the form "max (0, covariate -- constant)" which means that the value of the expression is that of covariate (e.g., weight) minus a constant for all values of covariate‐constant less than zero (i.e., for all values of covariate \< constant), otherwise it is zero value. The constant is at the hinge. Similar to its predecessor, a classification and regression tree that is commonly used for categorical dependent variables, MARS is used for a continuous dependent variable but also transforms data, groups, and then ranks predictors based on information theory. Thus, MARS can also be used for classification purposes and detection of high‐order interactions.[28](#psp412208-bib-0028){ref-type="ref"} Since MARS is a forward stepping spline regression model, it takes the functional form: $$f\left( x \right)~ = ~\beta{}_{0} + \Sigma\beta{}_{m}h_{m}x$$where h~m~(x) is a function of the BF.[25](#psp412208-bib-0025){ref-type="ref"} Lastly, MARS uses a generalized adjusted penalty and generalized cross‐validation to select the best set of BF to include in the models. The net effect is to produce smooth curves and surfaces such that residuals sum of squares are minimized and then demonstrating up to three‐way interactions between the dependent variable and predictors in 3D plots.

Statistical analysis {#psp412208-sec-0009}
--------------------

The D\'Agostino--Pearson omnibus normality test was used to check whether data were normally distributed. Comparison of clinical and demographic factors between groups, shown in **Table** [1](#psp412208-tbl-0001){ref-type="table-wrap"}, was made using either the Student\'s *t*‐test or Kruskal--Wallis test, while the Spearman rank correlation was used to demonstrate correlation between weight and age in all patients and then separately in males and females. Some continuous variables that were found to be important predictors in MARS were converted into categorical variables based on the BF obtained and then comparison between groups including gender made accordingly. Fisher\'s exact test or the χ[2](#psp412208-bib-0002){ref-type="ref"} test was used to compare proportions between groups, when appropriate. All tests were two‐sided; statistical significance was set at 0.05 and analyses were performed using STATA (v. 12, College Station, TX) and Prism (GraphPad v. 6.0, La Jolla, CA) software packages.

###### 

Demographic and clinical characteristics of 35 study participants[a](#psp412208-note-0001){ref-type="fn"}

  Demographic variable                           All                  Female               Male                 *P*‐value
  ---------------------------------------------- -------------------- -------------------- -------------------- -----------
  Study participants                             35 (100)             18 (51)              17 (49)              
  Self‐identified race *n* (%)                                                                                  
  White                                          29 (83)              15 (83)              14 (82)              0.94
  Non‐white                                      6 (17)               3 (17)               3 (18)               
  Co‐morbid conditions *n* (%)                   24 (69)              12 (67)              12 (71)              0.80
  Metabolic syndrome *n* (%)                     10 (29)                                                        
  Overweight or obese (BMI\>=25) *n* (%)         24 (69)              12 (67)              12 (71)              0.80
  Age (median \[range\]) years                   36 (21--77)          31 (21--57)          43 (23--77)          0.10
  Weight (median \[range\])                      85.1 (70.8--130.5)   79.2 (58--112.9)     89.2 (74.8--138.4)   0.18
  BMI (median \[range\])                         30.2 (23.6--43.9)    30.05 (22.9--43.7)   30.2 (24.4--43.9     0.70
  Serum creatine (median \[range\])              0.83 (0.68--0.99)    0.71 (0.63--0.76)    0.99 (0.9--1.06)     \<0.001
  Blood urea nitrogen (median \[range\]) mg/dl   13.0 (7--28)         12 (9--20)           13 (7--28)           0.07

Figures in parenthesis denote *n* = absolute number, () are percent, unless stated otherwise. Laboratory reference values: serum creatinine: men, 0.7--1.3 mg/dL; women 0.6--1.1 mg/dL; blood urea nitrogen: 6--20mg/dL.

RESULTS {#psp412208-sec-0010}
=======

We recruited 35 subjects; 24 (69%) were overweight or obese. Ten of these 24 people (42%) had metabolic syndrome. The distribution of BMI and weight are shown in **Figure** [1](#psp412208-fig-0001){ref-type="fig"}; these were not normally distributed, as demonstrated by a *P* \< 0.05 on D\'Agostino K^2^ normality test, fulfilling our experimental design intent. On the other hand, height (in meters), utilized in calculating the BMI metric, was normally distributed. **Table** [1](#psp412208-tbl-0001){ref-type="table-wrap"} shows the demographic characteristics of study participants; 51% were women and 49% men. There was no significant difference in weight, BMI, or the prevalence of comorbid conditions between men and women.

![Distribution of weight, BMI, and height in study participants. We tested the demographic factors that are part of the definition of overweight and obesity status for normality using the D\'Agostino K^2^ normality test. (**a**) BMI was not normally distributed, based on *P* \< 0.05. This reflected that we had succeeded in the experimental study design of recruiting participants whose BMIs were equally spread out between the 40 and 150 kg range. (**b**) Similarly, weight was not normally distributed, based on *P* = 0.007. (**c**) However, height, which is part of the definition of BMI, was found to be normally distributed.](PSP4-6-552-g001){#psp412208-fig-0001}

The concentration--time profiles in all subjects are shown in **Figure** [2](#psp412208-fig-0002){ref-type="fig"} **a**. The highest to lowest peak concentrations had a ratio of ∼10; all patients had received the same 100 mg dose of dapsone, illustrating the adage that a drug\'s dose is a poor surrogate for drug concentration. MLEM revealed results for model selection shown in **Supplementary Table S1**. Based on Akaike information criteria, Bayesian information criteria, and parsimony, a one‐compartment model was found to best describe dapsone pharmacokinetics. Observed vs. predicted concentrations for the 280 serum concentrations are shown in **Figure** [2](#psp412208-fig-0002){ref-type="fig"} **b** for the one‐compartment model. The base model parameters mean value, percent relative standard error (RSE), and standard deviation as a percent covariance were 1.85 L/h (37.3%) and 37.6% for systemic clearance, 64.0 L (23.4%) and 50.5% for volume, and 2.57/hr (102%) and 94.7% for absorption constant, respectively. The half‐life ± standard deviation was 25.2 ± 7.7 h, similar to observations in patients treated for a variety of infectious diseases.[1](#psp412208-bib-0001){ref-type="ref"}, [15](#psp412208-bib-0015){ref-type="ref"}, [21](#psp412208-bib-0021){ref-type="ref"}

![Concentration--time profile of dapsone in 35 participants. **(a)** All patients received the same dose of 100 mg a day. However, the concentrations achieved at each timepoint varied widely, so that the peak concentrations varied 1,000% between the lowest and highest concentrations. The median is shown, and illustrates why measures of central tendency such as median and mean ± standard deviation (which was 1.63 ± 1.03 mg/L) are poor descriptors of drug concentration estimates and their variability. Indeed, at no timepoint (except 24 h timepoint; *P* = 0.08) were the concentrations even normally distributed based on the D\'Agostino and Pearson omnibus normality test. **(b)** Observed vs. predicted dapsone concentrations for a one‐compartment model, showing an r^2^ = 0.91. The slope was 0.90 ± 0.02, and thus differed slightly from 1.00.](PSP4-6-552-g002){#psp412208-fig-0002}

Implementation of MARS identified the results shown in **Table** [2](#psp412208-tbl-0002){ref-type="table-wrap"}. The table shows that patient weight, age, and blood urea nitrogen (BUN) were identified and ranked as important covariates. **Table** [2](#psp412208-tbl-0002){ref-type="table-wrap"} also shows the final MARS model equations describing the effects of the three covariates on each of three one‐compartment model pharmacokinetic parameters. The most important predictor in MARS model in **Table** [2](#psp412208-tbl-0002){ref-type="table-wrap"} was set at 100% and the predictors remaining in the model after backward elimination weighed relative to the primary or most important predictor. Multiple variables that scored at 100% mean that they were equally important. Thus, in **Table** [2](#psp412208-tbl-0002){ref-type="table-wrap"}, for the absorption constant (K~a~), BUN is the primary predictor but weight contributes to the variance of dapsone K~a~ by 44% relative to the BUN. With regard to systemic clearance, patient\'s weight and age equally contributed to the clearance variance. On the other hand, for volume, only patient weight contributes to the variability.

###### 

Basis functions used to model the population pharmacokinetics of dapsone in adults.

  Outcome (Y)        Variable importance   Basis functions definitions   Model equations\*                         
  ------------------ --------------------- ----------------------------- ----------------------------------------- ---------------------------------------------
  K~a~ (hr^−1^)      BUN (mg/dL)           100%                          BF~1~ = max (0, BUN -- 7);                Y= 3.967 -- 0.062\*BF~3~ + 0.162\*BF~5~ (2)
                     Weight                44%                           BF~3~ = max (0, 63.7 -- Weight)\*BF~1~;   
                                                                         BF~5~ = max (0, 74.8 -- Weight)           
  Clearance (L/hr)   Weight                100%                          BF~2~ = max (0, 77.2 -- Weight);          Y = 2.048 -- 0.002BF~3~ -- 0.005BF~4~ (3)
                     Age                   100%                          BF~3~ = max (0, Age -- 27)\*BF~2~;        
                                                                         BF~4~ = max (0, 27 -- Age)\*BF~2~;        
  Volume (L)         Weight                100%                          BF~8~ = (0, Weight -- 69.8);              Y = 36.648 + 8.894BF~8~ -- 8.818BF~10~ (4)
                                                                         BF~10~ = max (0, Weight -- 74.8);         

BUN, blood urea nitrogen levels in mg/dl on initial blood sampling; weight, patient\'s weight in kg; variable importance denotes the weighted value of each variable in predicting the given dapsone pharmacokinetic parameter; the model equation is given by linear combination of basis functions. Up to a maximum of 15 basis functions were derived from the data allowing for a minimum of 3 (∼10%) of observations per knots and a maximum of 2^nd^ order interactions; then a backward step elimination selection process was used in the regression with moderate penalty for model complexity.

In the final equations (numbers 2--4) shown in **Table** [2](#psp412208-tbl-0002){ref-type="table-wrap"}, the covariates are given as BFs. **Figure** [3](#psp412208-fig-0003){ref-type="fig"} shows the relationship between weight and volume of distribution, reflecting BF~8~ \[max(0, Weight -- 69.8)\] and BF~10~ \[max (0, Weight -- 74.8)\]. The figure shows multiple hinges delimiting different slopes in the relationship, a perfect example the nonlinearity. A positive coefficient for a BF means that higher values of the covariate leads to higher values for the pharmacokinetic parameter, as shown for example in **Figure** [4](#psp412208-fig-0004){ref-type="fig"}. However, a negative coefficient means two things: either there is a reduction in the slope between the covariate and the dependent variable or there is a negative correlation between covariate and dependent variable (pharmacokinetic parameter).

![Depiction of basis functions of weight vs. volume of distribution. The figure illustrates two basis functions, BF~8~ and BF~10~, in Table 3. Depicted are hinges at patient weights of ∼70 kg and 75 kg, illustrating different slopes for the relationship between weight and volume.](PSP4-6-552-g003){#psp412208-fig-0003}

![The joint contribution of blood urea nitrogen and weight to dapsone absorption constant. The 3D plot demonstrates the interaction of hinge function and basis function for interaction of weight (WT) and blood urea nitrogen (BUN) to affect the absorption constant (K~a~).](PSP4-6-552-g004){#psp412208-fig-0004}

The second form of a BF is shown in **Figure** [4](#psp412208-fig-0004){ref-type="fig"}, which depicts BF~3~ in **Table** [2](#psp412208-tbl-0002){ref-type="table-wrap"} for absorption constant (K~a~), whereby the BF is a product of hinge functions or of hinge functions and a BF. BF~3~ is the product of a weight vs. K~a~ hinge function (max (0, 63.7 -- Weight)) and BF~1~ (i.e., max (0, BUN -- 7)). This BF is shown in the 3D covariate interaction plot of **Figure** [4](#psp412208-fig-0004){ref-type="fig"}. The expressions are conditional on the hinges from the parent BF. The interaction detection and selection of predictors is further shown in **Table** [3](#psp412208-tbl-0003){ref-type="table-wrap"}. The r^2^ reported in **Table** [3](#psp412208-tbl-0003){ref-type="table-wrap"} were obtained after general cross‐validation and thus give both reliability of the parameter estimates and robustness of the final model. As shown, weight explained 64% of the variance in dapsone volume.

###### 

Interactions detected and selection of predictors for dapsone pharmacokinetics based on MARS

  -------------------------------------------------------------------------------------------------------------------------------------
  Outcome (Y)        r^2^   Basis\                                             Coefficient   Variable   Sign   Parent   Knot     
                            function[a](#psp412208-note-0004){ref-type="fn"}                                                     
  ------------------ ------ -------------------------------------------------- ------------- ---------- ------ -------- -------- ------
  K~a~ (hr^−1^)      0.36   0                                                  3.967                                             

                            3                                                  −0.062        Weight     \+              BUN      63.7

                            5                                                  0.162         Weight     \+                       74.8

  Clearance (L/hr)   0.48   0                                                  2.049                                             

                            3                                                  −0.002        Age        \+     --       Weight   27

                            4                                                  −0.005        Age        --‐    --       Weight   27

  Volume (L)         0.64   0                                                  36.648                                            

                            8                                                  8.894         Weight     \+                       69.8

                            10                                                 −8.818        Weight     -- ‐                     74.8
  -------------------------------------------------------------------------------------------------------------------------------------

K~a~, absorption constant, BUN, blood urea nitrogen.

The basis functions are defined above; knot denotes the hinge or level at which values of the coefficient or slope of the regression changes.

In bivariate analysis, the median (interquartile) dapsone volume was significantly lower in women (66.43L; 39.89, 84.77) than men (86.60L; 71.7, 92.45), *P* = 0.027. However, this gender difference was lost in multivariate analyses of dapsone volume and therefore is not shown in the BF shown in **Table** [3](#psp412208-tbl-0003){ref-type="table-wrap"}. In addition, gender differences were not revealed when clearance and absorption constant values were examined in bivariate analyses. Median (interquartile) clearance was 1.92 (1.59, 2.26) L/h in females and 2.07 (1.95, 2.14) L/h in males.

DISCUSSION {#psp412208-sec-0011}
==========

Artificial intelligence algorithms, especially machine learning, are being increasingly employed to examine biological data.[29](#psp412208-bib-0029){ref-type="ref"}, [30](#psp412208-bib-0030){ref-type="ref"}, [31](#psp412208-bib-0031){ref-type="ref"}, [32](#psp412208-bib-0032){ref-type="ref"}, [33](#psp412208-bib-0033){ref-type="ref"}, [34](#psp412208-bib-0034){ref-type="ref"}, [35](#psp412208-bib-0035){ref-type="ref"}, [36](#psp412208-bib-0036){ref-type="ref"}, [37](#psp412208-bib-0037){ref-type="ref"}, [38](#psp412208-bib-0038){ref-type="ref"}, [39](#psp412208-bib-0039){ref-type="ref"} We started utilizing these for pharmacometric analyses almost 10 years ago.[3](#psp412208-bib-0003){ref-type="ref"}, [7](#psp412208-bib-0007){ref-type="ref"}, [10](#psp412208-bib-0010){ref-type="ref"} One of the algorithms, MARS, was used here to provide an agnostic (i.e., nonprespecified) identification of covariates responsible for interindividual variability of dapsone absorption, volume, and clearance, as well as their slopes. MARS evaluates both linear and nonlinear relationships simultaneously, as well as high‐order interactions of covariates among themselves and with primary pharmacokinetic parameters. In addition, it allows for regions where the relationships are discontinuous, or do not exist. Thus, MARS is able to identify multiple hinges delineating different slopes of the relationship between pharmacokinetic parameters and covariates for monotonic and nonmonotonic functions. Moreover, the main goal of machine‐learning methods such as MARS is predictive accuracy, and its use of cross‐validation techniques is highly reproducible in independent samples.[25](#psp412208-bib-0025){ref-type="ref"} We propose its routine use as a simplification of methods to identify significant covariates in general population pharmacokinetic analyses in a nonbiased and nonlinear fashion. This approach has important implications for the design of early phase clinical studies. Sample size, and thus risk of adverse events to patients, can be limited by application of optimal experimental design strategies, and the application of methods such as MARS for covariate selection. Further precision in estimating pharmacokinetic parameters would come from applying optimal sampling theory, which minimizes the number of samples to be drawn while improving accuracy, which could also reduce the patient sample size.

Using this approach, we found weight to be a significant covariate for dapsone absorption, volume, and systemic clearance. In the past, the role of weight has been examined assuming specific fractal geometry considerations for several antiinfective agents.[8](#psp412208-bib-0008){ref-type="ref"}, [9](#psp412208-bib-0009){ref-type="ref"}, [10](#psp412208-bib-0010){ref-type="ref"}, [17](#psp412208-bib-0017){ref-type="ref"}, [18](#psp412208-bib-0018){ref-type="ref"}, [19](#psp412208-bib-0019){ref-type="ref"}, [20](#psp412208-bib-0020){ref-type="ref"}, [22](#psp412208-bib-0022){ref-type="ref"} Our current approach with MARS bypasses the need to fix particular power laws with weight, by virtue of the fact that the final MARS equation derives its own coefficients, similar to letting exponents in fractal geometry "float." In other words, we did not fit any specific power law. Thus, it was our aim to be able to interpret both the model coefficients for inference and for predictions. Up to now, the understanding had been that dapsone systemic clearance increases linearly by 0.03 L/hr and volume by 0.7 L for each kg increase above 62 kg.[15](#psp412208-bib-0015){ref-type="ref"} Here we show that there were multiple hinges for the relationship between weight and systemic clearance (77.2 kg) and with volume (69.8 kg and 74.8 kg), which relationships were modified (i.e., interacted) by different hinges of age; the effect of weight on absorption constant was conditional on BUN. Interestingly, the weight hinges are all within close range of the value of 66.3 kg; the reasons are unclear. Thus, weight is an important covariate of primary dapsone pharmacokinetic parameters, but the relationships are complex and modified by the effect of age and renal function. To optimally treat obese patients with dapsone, therefore, we will need to personalize dosing recommendations by the patient\'s weight in order to account for their unique ability to absorb, distribute, metabolize, and eliminate this compound. One approach, which utilizes engineering simulations to achieve that, has been detailed before with other antiinfective agents.[40](#psp412208-bib-0040){ref-type="ref"}, [41](#psp412208-bib-0041){ref-type="ref"}

Dapsone systemic clearance had a hinge at the age of 27 years. This illustrates one of the advantages of the agnostic approach we took. First, BF~3~ and BF~4~ interact (modify) the effect of weight and are shown as multiplied with BF~2~. Second, BF~3~ and BF~4~ are termed mirror BFs: there is a reversal of slope below the hinge age of 27 years compared to above, and are thus nonlinear. Third, the hinge age of 27 years differs from the usual, and somewhat arbitrary, categorization of children as below 18 years old, and old age as beginning in the 60s. In pharmacokinetic terms, MARS avoids an arbitrary "typical" value for covariate, and instead identifies it from the data. Thus, one of the advantages of MARS is identification of such threshold values for covariates, without prior assumptions based on social and political categorization. Thus, the age at which a pharmacokinetic parameter changes is driven by the data for that pharmaceutical compound for that patient group, without the need for prior assumptions that categorize patients into convenient but arbitrary age groups.

Our study has strength and several limitations. The machine‐learning algorithms we used do not infer causality or mechanism. However, when combined with an experimental design, the approach gives insights into important nonlinear interactions that can be explored further as primary hypotheses. In this prospective clinical experiment, by design we recruited equal numbers of patients into different weight bands (as opposed to recruitment of all comers), deliberately recruited equal numbers for either gender, and the pharmacokinetic sample number and sampling times were identified using optimal sampling theory and D‐optimality in ADAPT. Another limitation was that in our study design, a single dapsone dose was administered to persons without active disease. The pharmacokinetic parameters of dapsone could be altered by the disease process it is administered to treat, by disease severity, and at steady state. However, the pharmacokinetic parameter estimates in our base model are similar to those observed by other investigators using multiple doses and/or evaluating patients with active disease.[15](#psp412208-bib-0015){ref-type="ref"}, [16](#psp412208-bib-0016){ref-type="ref"} We also did not evaluate routes of disposition or the effect of dapsone metabolites, so that we did not evaluate the physiological reasons why obese patients have higher drug metabolism.
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